Clinical bottom line
Recent advances in non-invasive biomarkers and diagnostic tests have improved early detection and risk stratification of alcohol-related liver disease (ALD), including its metabolic-associated variant (MetALD). Novel plasma proteins, imaging modalities, and combined proteo-transcriptomic approaches show promise in identifying subclinical liver injury and fibrosis before clinical decompensation. These tools may facilitate timely intervention and monitoring, potentially improving outcomes in ALD patients. However, validation in diverse populations and integration into clinical workflows remain ongoing challenges (Johansen et al., 2025; Gómez-Medina et al., 2023; Liang et al., 2026).
What the evidence shows
Johansen et al. (2025) provide a comprehensive review of non-invasive tests for MetALD and ALD, highlighting the utility of serum biomarkers such as cytokeratin-18 fragments and fibrosis scores combined with elastography techniques. They emphasize that multimodal approaches enhance diagnostic accuracy for early-stage disease.
Gómez-Medina et al. (2023) underscore the clinical need to detect subclinical ALD forms, noting that conventional liver function tests often lack sensitivity. They advocate for routine use of non-invasive fibrosis assessments to identify patients at risk of progression.
Liang et al. (2026) report on plasma insulin-like growth factor binding protein 7 (IGFBP7) as a novel biomarker improving risk reclassification for liver-related outcomes in ALD. Their proteo-transcriptomic profiling suggests IGFBP7 complements existing markers, refining prognostic models.
Silva et al. (2023) review fibrosis assessment tools in ALD, including transient elastography and serum panels, supporting their role in staging disease severity and guiding management.
Moreno et al. (2019) discuss the evolving landscape of biomarkers in ALD, including microRNAs and extracellular vesicles, which may provide insights into pathophysiology and therapeutic targets.
Tincopa et al. (2026) compare biomarkers across steatotic liver diseases, emphasizing the importance of distinguishing MetALD from metabolic dysfunction-associated steatotic liver disease (MASLD) to tailor interventions.
Lombardi et al. (2015) provide foundational data on non-invasive fibrosis assessment in ALD, supporting elastography’s role in clinical practice despite limitations in advanced cirrhosis.
Caveats and uncertainty
Many novel biomarkers require external validation in large, ethnically diverse cohorts.
Non-invasive tests may be confounded by coexisting liver diseases or acute inflammation.
Cutoffs for fibrosis staging vary among modalities, complicating standardization.
Longitudinal studies are needed to confirm predictive value for clinical outcomes.
Cost-effectiveness and accessibility of advanced biomarker assays remain concerns.
How this may change practice
Clinicians should consider incorporating validated non-invasive fibrosis assessments and emerging biomarkers into routine evaluation of patients with alcohol use disorder.
Early identification of subclinical ALD may prompt timely lifestyle interventions and monitoring, potentially delaying progression.
Multimodal diagnostic algorithms combining serum markers and imaging may improve risk stratification.
Ongoing research will refine biomarker panels and clarify their role in guiding therapy and prognosis.
Education on interpretation and limitations of non-invasive tests is essential for effective implementation.